Search for "viaskin peanut"

Dave Bloom - 2021/01/08 0

The company announced they would be laying off 200 employees in Q1.

News Wire ~ 3rd Party Press Release - 2019/07/11 0

FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.

Dave Bloom - 2019/07/11 0

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.

News Wire ~ 3rd Party Press Release - 2019/07/11 0

The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).

News Wire ~ 3rd Party Press Release - 2019/06/14 0

Affirms Burden of Food Allergies on Families, Patients, and Caregivers.

News Wire ~ 3rd Party Press Release - 2019/06/13 0

Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.

Dave Bloom - 2018/11/28 0

An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.

Dave Bloom - 2018/02/28 0

Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.

Dave Bloom - 2017/10/12 0

The phase III trial was designed to assess the safety and routine clinical use of Viaskin Peanut.

Dave Bloom - 2017/03/22 1

The study received higher-than-expected patient demand.

viaskin peanut - search results